April 2nd 2024
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen
April 29th 2020Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.
AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality Rates
March 11th 2020A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
Lower Risk of Melanoma Diagnosis and Increased Mortality Following Partner Bereavement
March 5th 2020These findings highlight the need to raise public awareness of the importance of self-skin examination, and to encourage clinicians to have a lower threshold for undertaking skin examinations in bereaved individuals, according to the researchers.
Poulikos Poulikakos, PhD, on Combining Targeted Therapy and Immunotherapy in Melanoma
November 26th 2019Poulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma
November 14th 2019Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?
September 3rd 2019A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.